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Volume 60, Number 4 Abstracts 1101Conclusions: This study demonstrates that CAS fractures are not
associated with an increased risk of restenosis. The true incidence of stent
fracture may be underestimated by x-ray analysis due to limited resolution
and frequent artifacts. Additional methods to evaluate for subtle CAS frac-
tures may assist in deﬁning a more precise incidence and might lead to
insight into the potential etiologies. Further evaluation with a larger study
population and a longer follow-up both for stent integrity and its association
with restenosis or adverse clinical outcomes is needed.
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Objectives: Inferior vena cava (IVC) thrombosis is an uncommon
condition but can cause devastating complications to those affected. Histor-
ically, this has been treated with an open surgical approach, with high
morbidity, and with angioplasty in more recent years. We describe technical
aspects of IVC stenting in patients with recalcitrant chronic occlusive disease
and evaluate its outcomes.
Methods: We reviewed all of the patients treated in an endovascular
fashion for venous pathology at our institution from 2005 to 2014 to iden-
tify and include those with IVC stent placement. Clinical characteristics,
treatment details, and outcomes data were collected using medical records.
Primary end points were technical success, symptom resolution, freedom
from reintervention, and patency rate at follow-up.
Results: Twenty-eight patients (15 males), with mean age of 48 6 14
years, underwent IVC stent placement for 16 occlusions (four congenital)
and 12 high-grade stenoses. Hypercoagulable state was noted in 14 pa-
tients, seven of whom had malignancy. A previously placed IVC ﬁlter was
present in 13 patients. Median time from onset of symptoms to
presentation was 81 months (range, 3-480 months). Lytic therapy with alte-
plase was performed in 12 patients for a mean of 2 6 1 days. Self-expanding
stents (Wallstent) were used in the IVC in 22 patients, with adjunctive use
of balloon-expandable (Palmaz) stents in seven patients. Technical success
was 100%. At a median follow-up of 10 months (range, 0-56 months),
thrombotic complications requiring reintervention occurred in four patients
at 1, 4, 8, and 37 months. One patient died at 2 weeks secondary to under-
lying malignancy. Freedom from reintervention, patency rate, and symp-
tom-free survival rate at 2 years were 84%, 90%, and 80%.
Conclusions: Endovascular stenting for chronic occlusive disease of
the IVC is safe, effective, and durable, with minimal morbidity. The reinter-
vention rate is low, with excellent outcomes.
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Objectives: This study evaluated outcomes of treated renal artery an-
eurysms (RAAs) and the natural history of observed RAAs.
Methods: A total of 114 patients with RAA managed from 1994 to
2014 were retrospectively reviewed. Primary outcomes included morbidity
and mortality of RAAs treated operatively (OP) with open and endovascular
procedures and aneurysm growth rate and risk of rupture in patients
managed nonoperatively (NOP). Secondary outcomes included renal artery
patency and need for reintervention in the OP group and kidney function in
the OP and NOP groups.
Results: There were 49 OP patients (34 females) and 66 NOP (31
females). Three RAAs ruptured (sizes: 34, 36, and 41 mm). Mean aneurysm
size was 26.8 6 8.9 mm (OP) and 13.6 6 5.2 mm (NOP; P < .001). A
total of 57% of patients in OP were symptomatic, with ﬂank pain (24%), he-
maturia (18%), and severe hypertension (18%). Nine (19%) and 29 (60%) of
OP patients had a RAA <20 and <30 mm, respectively. RAA location in the
OP included the primary bifurcation in 28, main renal artery in 8, upper and
lower segmental pole branches in 5 each, and middle segmental pole branch
in 2. Operative management included RAA resection and saphenous vein
graft (SVG) in 15, vein patch in 11, primary repair in 7, ex vivo reconstruc-
tion in 7, Dacron graft in 2, internal iliac artery patch in 1, and endovascularcoil embolization in 3. Mean renal ischemia time was 56 6 48 minutes (ex
vivo: 151 6 27 minutes; not ex vivo: 40 6 27 minutes). The 30-day mor-
tality was 0%. One patient had a nephrectomy at the time of repair due to
venous injury, and a second one occurred at 3.7 months due to SVG occlu-
sion. One patient underwent concomitant splenectomy. One patient’s oper-
ation was aborted due inﬂammation from a previously ruptured and coiled
RAA, who subsequently underwent deﬁnitive embolization. Complications
included pancreatitis (n ¼ 1) and reexploration for small bowel obstruction
(n ¼ 1) and bleeding (n ¼ 1). RAA reintervention was 0%. NOP RAAs were
followed up for 76.8 6 54.4 months and had a growth rate of 0.3 6 0.9
mm/y. There were no ruptures and no conversions to OP. Kidney function
in NOP remained stable (D glomerular ﬁltration rate, 5.4 6 21.1 mL/min)
but worsened in OP (D glomerular ﬁltration rate, 5.9 6 23.5 mL/min;
P ¼ .008).
Conclusions: No RAA <34 mm ruptured. Because the rate of
growth is slow and kidney function remains stable without repair, RAA
<30 mm should be observed unless symptoms occur.
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Objectives: Carotid endarterectomy (CEA) is usually performed with
eversion (ECEA) or conventional (CCEA) techniques. Previous studies
report conﬂicting results with respect to outcomes for ECEA and CCEA.
We compared patient characteristics and outcomes for ECEA and CCEA.
Methods: Deidentiﬁed data for CEA patients were obtained from the
Society for Vascular Surgery Vascular Quality Initiative database. Patients
undergoing reoperative CEA or CEA concurrent with cardiac surgery
were excluded, leaving 2828 ECEA and 20,831 CCEA for comparison.
Univariate analysis compared patients, procedures, and outcomes. Survival
analysis was also performed for primary outcomes of mortality, cerebral
ischemic events, restenosis, and reintervention.
Results: Groups were similar with respect to gender, comorbidities,
and preoperative neurologic symptoms, except that ECEA patients tended
to be older (71.3 vs 69.9 years; P < .0001). CCEA was more often per-
formed with general anesthesia (92% vs 81%; P < .001) and with a shunt
(59% vs 24%; P < .001). Perioperative ipsilateral neurologic events (ECEA,
1.3% vs CCEA, 1.2%; P ¼ .90) and any stroke (1.0% vs 0.8%; P ¼ .38)
were uncommon in both groups. ECEA tended to take less time (100 vs
113 minutes; P < .001) but more often required a return to the operating
room for bleeding (1.4% vs 0.8%; P ¼ .003). Kaplan-Meier 30 day freedom
from stroke or death was similar (97.7% vs 97.6%; P ¼ .17). The 1-year
freedom from recurrent stenosis >50% was lower for ECEA (88.9% vs
94.1%; P < .0001). However, ECEA and CCEA both had a very high rate
of freedom from reoperation at 1 year (99.6% vs 99.5%; P ¼ .98).
Conclusions: ECEA and CCEA appear to provide similar freedom
from neurologic morbidity, death, and reintervention. ECEA was associated
with signiﬁcantly shorter procedure times. Furthermore, ECEA obviates the
expenses of a patch, typically used in CCEA, and a shunt, more often used in
CCEA in this database. However, these potential beneﬁts may be reduced
by a slightly greater requirement for early return to the operating room
for bleeding.
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Objectives: This study assessed total costs for lower extremity
deep vein thrombosis (DVT) treatment using the Trellis device or
